Skip to main content
. Author manuscript; available in PMC: 2018 Feb 6.
Published in final edited form as: N Engl J Med. 2017 May 24;377(3):211–221. doi: 10.1056/NEJMoa1612790

Figure 4. Effects of Inhibition of ANGPTL3 with a Monoclonal Antibody on Triglyceride Levels in Human Volunteers.

Figure 4

The median percent change from baseline in the triglyceride level (measured in milligrams per deciliter) is shown for the placebo group and for the groups receiving evinacumab at various doses. Individual data points are median values, with I bars showing interquartile ranges.